DUBLIN – Prothena Corporation plc (NASDAQ:PRTA) announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, following the close of U.S. Financial markets. A live audio conference call is scheduled for 4:30 PM ET to discuss the results.
The biotechnology company, focused on late-stage clinical development of therapeutics for protein dysregulation, will host the call accessible via its website, www.prothena.com, under the Investors tab, within the Events and Presentations section. A replay of the webcast will be available on the company’s website for at least 90 days.
Investors and analysts can participate in the call via dial-in using the following numbers: +1 (800) 715-9871 (U.S. And Canada toll-free) or +1 (646) 307-1963 (international). The conference ID number is 1706941. A replay will be accessible until February 26, 2026, by dialing +1 (800) 770-2030 (U.S. And Canada toll-free) or +1 (609) 800-9909 (international), also using conference ID 1706941.
Prothena describes itself as a late-stage clinical biotechnology company specializing in protein dysregulation, aiming to address devastating neurodegenerative and rare peripheral amyloid diseases. The company’s research, built on decades of scientific expertise, focuses on a pipeline of therapeutic candidates targeting a range of indications, including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS).
The company’s approach leverages its proprietary CYTOPE® technology, designed to target intracellular disease pathways in both the brain and peripheral tissues. Prothena’s pipeline includes both wholly-owned programs and partnered collaborations.
The announcement comes as the biotechnology sector continues to attract significant investor attention, particularly companies focused on neurological disorders. The development of effective treatments for diseases like Alzheimer’s and Parkinson’s remains a high priority for both pharmaceutical companies and the medical community, given the increasing prevalence of these conditions with aging populations.
Prothena’s focus on protein dysregulation represents a specific area within neurological research. Misfolded proteins are increasingly recognized as a key factor in the progression of many neurodegenerative diseases, making companies like Prothena, with expertise in this area, potentially valuable players in the development of new therapies.
Investors will be closely watching the February 19th earnings report for updates on the progress of Prothena’s clinical trials, particularly those related to its lead candidates. Key metrics to be monitored will include trial enrollment rates, safety data, and preliminary efficacy results. The company’s financial performance, including revenue, research and development expenses, and cash burn rate, will also be scrutinized.
The company’s investor relations contact is Mark Johnson, CFA, Vice President, Investor Relations, reachable at IR@prothena.com or 650-837-8550. Media inquiries can be directed to Media@prothena.com.
